Vanda Pharmaceuticals Inc.
NASDAQ:VNDABiotechnology
-$0.20 today
- Market cap
- $226.76M
- Beta
- 0.60
- P/E (TTM)
- -1.4
- EPS (TTM)
- -$4.03
Volume 0.95M
Average 1.29M
VNDA Retained Earnings
Cumulative profits kept in the business rather than paid out as dividends.
Vanda Pharmaceuticals Inc.NASDAQ: VNDA
Retained Earnings · Q1 FY2026 · quarter ended Mar 2026
Retained earnings remains negative
Q1 FY2026 retained earnings was -$443.33M, compared with -$203.79M a year earlier.
Context
- Retained earnings amounted to 102.3% of total assets at the end of Q1 FY2026, up 70.0 pp from a year earlier.
- Retained earnings grew in size in 2 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether retained earnings keeps falling in the next quarterly balance sheet after a -117.5% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Retained Earnings history
USD · from the balance sheet
- Latest · FY2025
- (394.77M) USD
- Year-over-year change
- -126.5%
| Period | Period end | Retained Earnings | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (394.77M) | -126.5% |
| FY2024 | 2024-12-31 | (174.29M) | -12.2% |
| FY2023 | 2023-12-31 | (155.39M) | +1.6% |
| FY2022 | 2022-12-31 | (157.9M) | +3.8% |
| FY2021 | 2021-12-31 | (164.18M) | — |
Retained Earnings vs competitors
How VNDA compares with its peers on the latest reported figures
- VNDA's Mar 2026 retained earnings of -$443.33M is the 5th highest of the 11 companies compared; the peer median is -$507.7M.
- Its year-over-year change of -117.5% is the 10th highest of 11, against a peer median of -28.2%.
- Retained earnings amounts to 102.3% of total assets for VNDA, versus a peer median of 218.4%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | -$270.39M | -23.8% | — | 816.8% | |
| Mar 2026 | -$312.81M | -113.2% | — | 93.2% | |
| Mar 2026 | -$338.82M | -51.1% | — | 103.8% | |
SGMTSagimet Biosciences Inc. | Mar 2026 | -$357M | -13.9% | — | 331.3% |
| Mar 2026 | -$443.33M | -117.5% | — | 102.3% | |
| Mar 2026 | -$473.84M | -32.7% | — | 216.0% | |
| Mar 2026 | -$541.55M | -17.0% | — | 220.7% | |
| Mar 2026 | -$568.01M | -42.5% | — | 212.7% | |
| Mar 2026 | -$744.47M | -15.1% | — | 673.4% | |
| Mar 2026 | -$2.05B | -9.2% | — | 518.6% | |
| Mar 2026 | -$293.78B | -122645.6% | — | 136.8% | |
| Peer median (excluding VNDA) | -$507.7M | -28.2% | — | 218.4% | |
Competitors are the stored peer set for VNDA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 52.07M | 135.03M | 135.82M | 102.32M | 84.85M |
| Short-term Investments | 380.74M | 331.83M | 252.44M | 272.33M | 179M |
| Net Receivables | 32.47M | 33.51M | 34.16M | 47.1M | 54.58M |
| Inventory | 1.02M | 1.19M | 1.36M | 1.73M | 1.85M |
| Other Current Assets | 1 | 17.73M | 9.17M | 15.42M | 26.99M |
| Total Current Assets | 478.3M | 519.29M | 432.95M | 438.89M | 347.26M |
| Property, Plant & Equipment (Net) | 12.39M | 10.97M | 9.14M | 12.68M | 13.51M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 20.08M | 18.57M | 121.37M | 114.1M | 117.09M |
| Long-term Investments | 0 | 0 | 0 | 0 | 0 |
| Tax Assets | 74.88M | 74.04M | 75M | 81.44M | 0 |
| Other Non-current Assets | 8.15M | 11.38M | 9.99M | 9.1M | 11.08M |
| Total Non-current Assets | 115.49M | 114.96M | 215.49M | 217.31M | 141.69M |
| Total Assets | 593.79M | 634.25M | 648.44M | 656.2M | 488.95M |
| Account Payables | 925K | 12.69M | 7.15M | 3.5M | 4.94M |
| Short-term Debt | 0 | 0 | 0 | 0 | 0 |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 27.68M | 34.01M | 69.33M | 69.36M | 87.19M |
| Total Current Liabilities | 74.42M | 91.44M | 87.7M | 99.98M | 145.16M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 4.39M | 6.8M | 8.83M | 9.59M | 9.53M |
| Total Non-current Liabilities | 14.45M | 15.61M | 15.83M | 17.68M | 16.6M |
| Total Liabilities | 88.86M | 107.05M | 103.53M | 117.66M | 161.76M |
| Common Stock | 56K | 57K | 58K | 58K | 59K |
| Retained Earnings | (164.18M) | (157.9M) | (155.39M) | (174.29M) | (394.77M) |
| Accumulated OCI | (175K) | (1.19M) | (30K) | 74K | 629K |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 504.93M | 527.2M | 544.91M | 538.55M | 327.19M |
| Total Debt | 12.37M | 11.14M | 9.4M | 12.36M | 12.62M |
| Net Debt | (39.71M) | (123.89M) | (126.42M) | (89.96M) | (72.23M) |
Vanda Pharmaceuticals Inc.
NASDAQ:VNDA
Intrinsic Alpha fair value
Locked
Current Price
$3.75
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.